Beijing Health Guard Biotechnology
CompanyChina
Beijing Health Guard Biotechnology develops one asset, in phase 3 (Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in human papillomavirus infection). Mostly vaccine; based in China.
- 1
- Asset
- Furthest stage
- Phase 3
- 5
- Trials
- 1
- Signal
Pipeline
1Induces protective immunity against nine human papillomavirus types to prevent infection and associated disease.
Phase 3, Vaccine, human papillomavirus infection, human papilloma virus infection (Phase 2)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials5
- Signals1
- Similar companies2